non-toxicity

Maculosin is a secondary metabolite of fungi and bacteria.

(R)-Carvedilol is a non-selective blocker of β/α-1. (R)-Carvedilol exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).

(S)-Carvedilol is a non-selective β/α-1 blocker.It exerts protection against the vascular or cardiac toxicity of Doxorubicin (DOX).

Ethyl phenylacetate is a "greener" solvent with low toxicity. Ethyl phenylacetate is a non-mutagenic and is a Kosher food additive. Ethyl phenylacetate gives the wines a strong honey-like character. Ethyl phenylacetate is a natural flavoring ingredient, and its sensory threshold is near 73 µg/L. 

Chlorazanil is a triazine-derived compound that functions as a novel, orally active, and non-toxic diuretic. Chlorazanil exerts its pharmacological effect by selectively blocking sodium and chloride ion reabsorption in the distal renal tubule, promoting diuresis and modulating electrolyte balance without inducing significant systemic toxicity, in addition, chlorazanil increases renal prostaglandin activity by increased prostaglandin synthesis,marking it as a valuable agent in renal physiology research and diuretic drug development.

NSC745885 is an antitumor agent non-toxic to normal cells that downregulates EZH2 via proteasome-mediated degradation. It exhibits toxicity against multiple normal and drug-resistant cancer cell lines and may be used in studies of advanced bladder cancer and oral squamous cell carcinoma.

HRX-0233 is a small-molecule MAP2K4 inhibitor that induces strong tumor regression without apparent toxicity in KRASG12C-mutant non-small cell lung cancer models, prevents receptor tyrosine kinase feedback activation during sotorasib monotherapy. HRX-0233 achieves sustained MAPK pathway suppression, supporting its application in lung, colon, and AR-negative prostate cancer research.

hAChE-IN-9 (compound 7i) is a selective inhibitor of human acetylcholinesterase (hAChE), showcasing inhibition activities with IC50 values of 0.05 μM for AChE and 2.85 μM for BChE. This compound modulates toxic Aβ oligomers into non-toxic forms and offers antioxidant and neuroprotective effects against Aβ-induced toxicity. hAChE-IN-9 is employed in the study of Alzheimer's disease.

Prallethrin is an airborne mosquito repellent and a non-fluorinated pyrethroid that targets lung surfactant proteins (SPs). It exhibits vapor toxicity and can bind to SPs through hydrogen bonding and hydrophobic interactions, impairing their function. Prallethrin is utilized in research concerning respiratory diseases, pathogenic infections, and malignant tumors.

PI3Kδ/HDAC6-IN-1 (Compound 22E) is an orally active dual inhibitor of PI3Kδ and HDAC6, with IC50 values of 2.4 nM and 6.2 nM, respectively. It exhibits potent antiproliferative effects against non-Hodgkin's lymphoma (NHL) cells and demonstrates antitumor activity in vivo without significant toxicity. PI3Kδ/HDAC6-IN-1 induces cell cycle arrest at the G0/G1 phase and triggers apoptosis. Additionally, it inhibits the PI3K/AKT/mTOR signaling pathway and enhances the acetylation levels of α-tubulin and histone H3.

DHI1 is an anti-leukemia agent with high selectivity towards Jurkat (IC50= 21.83 μM) and HL-60 (IC50= 19.14 μM) leukemia cells, while exhibiting low toxicity to non-cancerous cells. It induces G2/M cell cycle arrest in both Jurkat and HL-60 leukemia cells and S phase arrest in HL-60 cells, significantly affecting cell cycle signaling molecules such as Wee1, cyclin B1, cdc2 on Tyr15, and Chk1. DHI1 inhibits the migration and invasiveness of Jurkat and HL-60 cells by disrupting the cytoskeletal actin filaments, making it useful for research on hematological malignancies.

HSP70-IN-7 is a non-selective HSP70 inhibitor with dissociation constants (Kd) of 4.71, 2.16, and 2.93 μM for HSP70, GRP75, and GRP78, respectively. It exhibits selective toxicity toward breast cancer cells, induces apoptosis, and effectively inhibits the characteristics of breast cancer stem cells (BCSC). HSP70-IN-7 is useful for breast cancer research.

PDK1-IN-5 is a selective inhibitor of PDK1 that reduces phosphorylation levels to activate PDH. This compound effectively reverses the Warburg effect by increasing acetyl-CoA, reducing lactate, elevating mitochondrial ROS, and subsequently inducing apoptosis, shifting cellular energy metabolism from glycolysis to oxidative phosphorylation. PDK1-IN-5 strongly inhibits tumor growth in vivo without causing systemic toxicity and can be used in research on lung adenocarcinoma, human non-small cell lung adenocarcinoma, gastric cancer, and colorectal cancer.

DHODH-IN-33 is a selective DHODH inhibitor that exhibits potent activity against A549 cells (IC50 = 5.22 μM) and 5637 cells (IC50 = 3.03 μM). It induces autophagy-dependent ferroptosis, characterized by mitochondrial dysfunction, lipid peroxidation, and accumulation of ROS, without significant toxicity in vivo. The anticancer effect of DHODH-IN-33 is achieved through promoting autophagy-dependent degradation of dihydroorotate dehydrogenase. This compound can be used in studies related to non-small cell lung cancer and bladder cancer.

DD-CIP2 is a DNA damage inducer that triggers significant DNA damage, cell cycle arrest, and apoptosis by modulating DNA damage response pathways. It demonstrates notable antitumor efficacy without apparent toxicity at well-tolerated doses in vivo. Its exceptional cytotoxicity against a range of cancer cell lines from hematological and solid tumors is independent of their BRCA1/2 status. DD-CIP2 can be utilized in research on small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

Axl-IN-21 is an orally bioavailable selective AXL inhibitor with a Kd of 2.7 nM and an IC50 of 4.0 nM. It demonstrates strong inhibitory activity against various cancer-related kinases while maintaining kinase selectivity, including Mer (Kd = 1.4 nM), DDR1 (IC50 = 22.2 nM), HIPK4 (Kd = 11.0 nM), and LOK (Kd = 10 nM). By blocking the AXL/STAT3/ABCG1 signaling pathway induced by GAS6 from tumor-associated fibroblasts, Axl-IN-21 can overcome tumor microenvironment-driven resistance, restore chemotherapy sensitivity, and inhibit drug efflux. In MDA-MB-231 cells, it inhibits TGF-β1-induced epithelial-mesenchymal transition, cell migration, and invasion. Axl-IN-21 exhibits no significant toxicity to non-cancer cells and is relevant for research in triple-negative breast cancer and gastric cancer.

Anticanceragent 289 is an H2O2-responsive anticancer prodrug. It demonstrates H2O2-induced DNA alkylation activity and selectively inhibits the proliferation of cancer cells with high ROS expression, compared to non-malignant cells. It significantly suppresses tumor growth in vivo without visible toxicity. Anticanceragent 289 is applicable for research in triple-negative breast cancer (TNBC).

TMC647055 Choline Hydroxide Salt is a novel and potent non-nucleoside inhibitor of the HCV NS5B polymerase which potentially for the treatment of HCV infection. It has nanomolar cellular potency (EC(50) of 82 nM) with minimal associated cell toxicity (CC(

Hexythiazox is a mite growth regulator and a thiazolidine based acaricide that has long-lasting effects against many kinds of mites and is applied at any stage of the plant growth from budding to fruiting.

LY2389575 hydrochloride is an mGlu3 negative allosteric modulator (NAM) that is selective and non-competitive, with an IC50 value of 190 nM. LY2389575 hydrochloride induces an increase in the level of Mrc1, which amplifies the toxicity of β-amyloid (Aβ), and can be used to study Alzheimer's disease. It can be used to study Alzheimer's disease.

Avitinib (AC0010), also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity. Upon oral administration, avitinib covalently binds to and inhibits the activity of mutant forms of EGFR, including the drug-resistant T790M EGFR mutant, which prevents signaling mediated by mutant forms of EGFR. This may both induce cell death and inhibit tumor growth in EGFR-mutated tumor cells. EGFR, a receptor tyrosine kinase that is mutated in a variety of Ys, plays a key role in tumor cell proliferation and tumor vascularization. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced when compared to non-selective EGFR inhibitors, which also inhibit wild-type EGFR.

Fluensulfone (MCW-2) is a new nematicide of the fluoroalkenyl thioether group that has significantly reduced environmental impact with low toxicity to non-target insects and mammals.

C8 Galactosylceramide is a synthetic C8 short-chain derivative of known membrane microdomain-forming sphingolipids. It increases the amount delivered and toxicity of doxorubicin in cancerous but not non-cancerous cells when incorporated into the nanoliposomal membrane of nanoliposomal-doxorubicin. C8 Galactosylceramide induces proliferation and cytokine production by splenocytes in vitro at concentrations ranging from 100-1,000 ng/ml but has no effect on natural killer T cell production in vivo. It also activates NF-κB production in C6 glioma cells when used at a concentration of 10 μM.

TunR1 is an antibiotic and derivative of tunicamycin .1It is active againstB. subtilis(MIC = 0.3 μg/ml) and increases the efficacy of the β-lactam antibiotics oxacillin , methicillin , and penicillin G againstB. subtiliswhen used at a concentration of 0.4 μg/ml. TunR1 (5 μg/ml) is cytotoxic to MDA-MB-231 breast cancer cells and non-cancerous CHO cells. Unlike tunicamycin, TunR1 does not inhibit glycosylation in a protein N-glycosylation assay. 1.Price, N.P., Hartman, T.M., Li, J., et al.Modified tunicamycins with reduced eukaryotic toxicity that enhance the antibacterial activity of β-lactamsJ. Antibiot. (Tokyo)70(11)1070-1077(2017)